RecruitingNCT06870006

Psychotropic-Drug-induced QT Prolongation and ECG Monitoring in the Pediatric Population


Sponsor

Meyer Children's Hospital IRCCS

Enrollment

100 participants

Start Date

Jan 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Electrocardiogram (ECG) Q-T prolongation is a cardiac electrophysiological disorder associated with the occurrence of arrhythmias potentially fatal. Several psychotropic drugs are associated with an increased risk of QT prolongation, which is why in clinical practice a baseline ECG is performed before a psychotropic drug is prescribed. However, there are no validated protocols establishing when to repeat this examination or describing clinical events when this examination should be repeated in clinical follow-up. The study aims to investigate the incidence of QTc prolongation events as a side effect of chronic psychotropic drug administration. For this purpose, ECGs will be recorded and confounding factors of patients at the beginning of psychotropic therapy and after 3, 6 and 12 months will be analyzed.


Eligibility

Max Age: 18 Years

Inclusion Criteria2

  • Admitted to psychiatry ward
  • Starting a psychotropic drug acting on QT interval

Exclusion Criteria2

  • Age \>18aa
  • History of administration of drug acting on QT interval in the 3 months prior

Locations(6)

Neuropsichiatria Infantile, IRCCS - OC Associazione Oasi Maria SS. ONLUS

Troina, Enna, Italy

AOU Meyer IRCCS

Florence, FI, Italy

IRCCS Fondazione Stella Maris

Calambrone, Pisa, Italy

Neuropsichiatria infantile, Policlinico S.Orsola-Malpighi

Bologna, Italy

Clinica di Neuropsichiatria dell'Infanzia e dell'adolescenza, Ospedale Pediatrico A. Cao ARNAS G. Brotzu

Cagliari, Italy

Neuropsichiatria Infantile, Azienda Ospedaliera-Universitaria "Gaetano Martino"

Messina, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06870006


Related Trials